The outlier today is a career piece, but it is still useful for trainees and early-career neurologists. It pushes back against all-or-nothing thinking about research, links patient and advocacy-group work to meaning, and names post-training worry as a real early-career trap.

This is the most future-facing listen today. It is less about current bedside decisions than about what amyloid blood tests or PET positivity in cognitively unimpaired people may mean for prevention trials, delayed cognitive impairment, and the coverage and access work needed before use widens.

When CSF testing is being planned for suspected leptomeningeal metastasis, the useful question is what answer the team actually needs. This episode separates cytology, circulating tumour cell assays, and cell-free DNA, and it is strongest on why a positive cell-free DNA result does not itself prove malignant cells in the CSF.

New migraine drugs often generate excitement before the evidence is ready. This update stays grounded: phase 2 data show dose-responsive gains in pain and associated symptoms, but paraesthesias and feeling warm increase with dose, and routine use still waits for confirmatory trials.

Policy is the main subject here. Its use is separating a proposed budget cut from an enacted change, then linking bills and CMS consultation to real effects on research funding, treatment access, benefit timing, documentation, and billing.

Keep this for evidence triage rather than bedside answers. The value is the reminder that a conference preview can flag high-impact neurology studies, but full trial methods and results still need review before any change reaches routine care.

Brief but practical for anyone who reads practice-changing papers. Letters and author replies show where the real disagreement sits, clarify what a study was trying to say, and stop publication being treated as the end of scrutiny.

The reason not to reassure yourself with existing migraine options is the unmet need this short update names. It explains why TRPM8 blockade is being tested when acute therapies work inadequately or inconsistently, while keeping the line clear between biological promise and proven benefit.

The pressure point is operational strain that starts to touch patient care. This short listen is useful for anyone leading a service, because it separates funding, staffing, administration and care delivery pressures and turns a vague sense of overload into something a team can act on.

The clue is rising seizure frequency or a request for dose review during pregnancy, especially with lamotrigine. Open this for a practical schedule: regular antenatal increases, a taper starting about two days after delivery, and a postpartum target still slightly above baseline.